

CITATION REPORT

List of articles citing

Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis

DOI: 10.1007/s40265-021-01650-7
Drugs, 2021, 82, 55.

Source: <https://exaly.com/paper-pdf/135567035/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
7	Favourable additional safety data for ofatumumab.		
6	How to choose initial treatment in multiple sclerosis patients: a case-based approach. 2022 , 80, 159-172		
5	What Do We Know So Far about Ofatumumab for Relapsing Multiple Sclerosis? A Meta-Analytical Study. 2022 , 10, 2199		○
4	Biologics targeting CD20 molecule on B cells in the therapy of multiple sclerosis patients. 2022 , 23, 488-491		○
3	An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis. 2023 ,		○
2	Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?. 2023 , 16, 175628642211371		○
1	S1PR1 modulators in multiple sclerosis: Efficacy, safety, comparison, and chemical structure insights. 2023 , 250, 115182		○